Myocardial infarction, commonly known as a heart attack, is one of the most serious heart problems people can face. It happens when blood flow to a part of the heart muscle is suddenly blocked.

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...

- Reduced inflammation at the site of myocardial infarction and improved heart function demonstrated. Novel therapy to modulate immune response with apoptotic cell-derived nanovesicles. Myocardial ...

Myocardial ischemia is a drop in blood flow to the heart. Myocardial infarction, or heart attack, occurs when death or damage occurs in the muscle tissue of the heart due to low blood supply. The ...

Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern ...

Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...

In a recent article published in the journal Nature Medicine, researchers discuss a novel clinical decision support system based on machine learning (ML) models to predict an individual’s probability ...